Using the International Pandemic Instrument to Revitalize the Innovation Ecosystem for Antimicrobial R&D 

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Using the International Pandemic Instrument to Revitalize the Innovation Ecosystem for Antimicrobial R&D . / Morales Caceres, Andrea; Kumar Singh, Kshitij ; Minssen, Timo; Hoffman, Steven J. ; Van Katwyk, Susan Rogers.

In: Journal of Law, Medicine & Ethics, Vol. 50, No. S2 (Winter 2022), 2022, p. 47-54.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Morales Caceres, A, Kumar Singh, K, Minssen, T, Hoffman, SJ & Van Katwyk, SR 2022, 'Using the International Pandemic Instrument to Revitalize the Innovation Ecosystem for Antimicrobial R&D ', Journal of Law, Medicine & Ethics, vol. 50, no. S2 (Winter 2022), pp. 47-54. https://doi.org/10.1017/jme.2022.79

APA

Morales Caceres, A., Kumar Singh, K., Minssen, T., Hoffman, S. J., & Van Katwyk, S. R. (2022). Using the International Pandemic Instrument to Revitalize the Innovation Ecosystem for Antimicrobial R&D . Journal of Law, Medicine & Ethics, 50(S2 (Winter 2022)), 47-54. https://doi.org/10.1017/jme.2022.79

Vancouver

Morales Caceres A, Kumar Singh K, Minssen T, Hoffman SJ, Van Katwyk SR. Using the International Pandemic Instrument to Revitalize the Innovation Ecosystem for Antimicrobial R&D . Journal of Law, Medicine & Ethics. 2022;50(S2 (Winter 2022)):47-54. https://doi.org/10.1017/jme.2022.79

Author

Morales Caceres, Andrea ; Kumar Singh, Kshitij ; Minssen, Timo ; Hoffman, Steven J. ; Van Katwyk, Susan Rogers. / Using the International Pandemic Instrument to Revitalize the Innovation Ecosystem for Antimicrobial R&D . In: Journal of Law, Medicine & Ethics. 2022 ; Vol. 50, No. S2 (Winter 2022). pp. 47-54.

Bibtex

@article{4716ae9dc1f747c7aecf9fd358aa6992,
title = "Using the International Pandemic Instrument to Revitalize the Innovation Ecosystem for Antimicrobial R&D ",
abstract = "The inclusion of antimicrobial resistance (AMR) and increased research and development (R&D) capabilities in the most recent outline of the World Health Organization{\textquoteright}s (WHO{\textquoteright}s) international pandemic instrument signals an opportunity to reshape pharmaceutical R&D system in favour of antimicrobial product development. This article explains why the current innovation ecosystem has disadvantaged the creation of antimicrobial products for human use. It also highlights how the COVID-19 pandemic experience can inform and stimulate international cooperation to implement innovative R&D incentives to bring new, life-saving antimicrobial products to the market.",
keywords = "Faculty of Law, AMR, pandemic treaty, law, ethics",
author = "{Morales Caceres}, Andrea and {Kumar Singh}, Kshitij and Timo Minssen and Hoffman, {Steven J.} and {Van Katwyk}, {Susan Rogers}",
year = "2022",
doi = "10.1017/jme.2022.79",
language = "English",
volume = "50",
pages = "47--54",
journal = "Journal of Law, Medicine & Ethics",
issn = "1073-1105",
publisher = "Cambridge University Press",
number = "S2 (Winter 2022)",

}

RIS

TY - JOUR

T1 - Using the International Pandemic Instrument to Revitalize the Innovation Ecosystem for Antimicrobial R&D 

AU - Morales Caceres, Andrea

AU - Kumar Singh, Kshitij

AU - Minssen, Timo

AU - Hoffman, Steven J.

AU - Van Katwyk, Susan Rogers

PY - 2022

Y1 - 2022

N2 - The inclusion of antimicrobial resistance (AMR) and increased research and development (R&D) capabilities in the most recent outline of the World Health Organization’s (WHO’s) international pandemic instrument signals an opportunity to reshape pharmaceutical R&D system in favour of antimicrobial product development. This article explains why the current innovation ecosystem has disadvantaged the creation of antimicrobial products for human use. It also highlights how the COVID-19 pandemic experience can inform and stimulate international cooperation to implement innovative R&D incentives to bring new, life-saving antimicrobial products to the market.

AB - The inclusion of antimicrobial resistance (AMR) and increased research and development (R&D) capabilities in the most recent outline of the World Health Organization’s (WHO’s) international pandemic instrument signals an opportunity to reshape pharmaceutical R&D system in favour of antimicrobial product development. This article explains why the current innovation ecosystem has disadvantaged the creation of antimicrobial products for human use. It also highlights how the COVID-19 pandemic experience can inform and stimulate international cooperation to implement innovative R&D incentives to bring new, life-saving antimicrobial products to the market.

KW - Faculty of Law

KW - AMR

KW - pandemic treaty

KW - law

KW - ethics

U2 - 10.1017/jme.2022.79

DO - 10.1017/jme.2022.79

M3 - Journal article

C2 - 36889345

VL - 50

SP - 47

EP - 54

JO - Journal of Law, Medicine & Ethics

JF - Journal of Law, Medicine & Ethics

SN - 1073-1105

IS - S2 (Winter 2022)

ER -

ID: 312845009